Search - tctmd.com

Displaying 221 - 240 of 261

Sort: Relevancy | Date

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Ashley Lyles

June 20, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

Yael L. Maxwell

February 14, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Daily News

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Michael O'Riordan

March 25, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

Advertisement

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content